GSK plc
GLAXF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $70.1M in total; no superinvestor holds it.
Other share classesGSK
13F holders, Q4 2023
Institutional positions in GSK plc as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 2
- 0 vs. Q3 2023
- Shares held
- 3.54M
- +115.6K (+3.4%) vs. Q3 2023
- Total value
- $65.4M
- +$3.03M (+4.9%) vs. Q3 2023
- New holders
- 0
- 2 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GLAXF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $70.1M |
| Q1 2026 | 2 | $77.9M |
| Q4 2025 | 1 | $73.8M |
| Q3 2025 | 2 | $64.1M |
| Q2 2025 | 1 | $60.0M |
| Q1 2025 | 1 | $58.2M |
| Q4 2024 | 2 | $56.8M |
| Q3 2024 | 2 | $70.3M |
| Q2 2024 | 2 | $68.3M |
| Q1 2024 | 2 | $76.8M |
| Q4 2023 | 2 | $65.4M |
| Q3 2023 | 2 | $62.4M |
| Q2 2023 | 2 | $61.2M |
| Q1 2023 | 1 | $53.9M |
| Q4 2022 | 1 | $53.4M |
| Q3 2022 | 1 | $44.5M |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding GSK plc; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Aristotle Capital Management, LLC | 3,420,296 | $63.2M | 0.12% | +85,420+2.6% | Added |
| Kennedy Capital Management, Inc. | 122,080 | $2.25M | 0.05% | +30,179+32.8% | Added |